Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials

Jian-Kun Hu, Zhi-Xin Chen, Zong-Guang Zhou, Bo Zhang, Jing Tian, Jia-Ping Chen, Li Wang, Chao-Hua Wang, Hong-Yan Chen, You-Ping Li

Jian-Kun Hu, Zhi-Xin Chen, Zong-Guang Zhou, Bo Zhang, Jing Tian, Jia-Ping Chen, Chao-Hua Wang, Hong-Yan Chen, General Surgery Department, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China
Li Wang, You-Ping Li, Chinese Evidence-Based Medicine/Cochrane Center, Chengdu 610041, Sichuan Province, China
Supported by the Scientific Foundation of Chinese Cochrane Center (EBM200114) and the key project of national outstanding young foundation of China (No39925032)
Correspondence to: Drs. Jian-Kun Hu and Zong-Guang Zhou, General Surgery Department, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, China. fjklcm1111@hotmail.com
Telephone: +86-28-85422479
Received 2002-03-13 Accepted 2002-04-20

Abstract
AIM: To assess the safety and efficacy of different intravenous chemotherapeutic regimens in patients with gastric carcinomas who had undergone gastrectomy.

METHODS: A meta-analysis of all the relevant randomized controlled trials (RCTs) was performed. Language was restricted to Chinese and English. RCTs were identified from Medline and Embase (1980-2001/4), and Chinese Biomedical Database (1990-2001/1). Literature references were checked at the same time. We included randomized and quasi-randomized trials comparing the efficacy of intravenous chemotherapy after gastrectomy with that of surgery alone in patients with confirmed gastric carcinomas who had undergone gastrectomy. Selection criteria were: randomized or quasi-randomized trials with following-up results; Trials could be double-blind, single-blind or not blind; Chemotherapy groups were given intravenous chemotherapy after gastrectomy without neo-adjuvant chemotherapy, intraperitoneal hyperthermic perfusion, radiotherapy or chemoinmunotherapy; Controlled group included those receiving gastrectomy alone. The following data were extracted: the number of survival and death by the end of the follow-up; the different agents and doses of the intravenous chemotherapy; the baseline of the chemotherapy group and the controlled arm; the serious adverse events; the statistical consideration; cost-effectiveness analysis. The statistical analysis was performed by RevMan4.1 software which was provided by the Cochrane Collaboration. A P value of <0.05 was considered statistically significant. Meta-analysis was done with random effects model. Heterogeneity and sensitivity analysis were performed also. The effect of intravenous chemotherapy after gastrectomy was better than surgery alone (odds ratio 0.56, 95 % CI 0.40-0.79). There was a significant difference between the two groups by u-test (P=0.0008). Sensitivity analysis revealed the same difference (odds ratio 0.81, 95 % CI 0.70-0.94). Of fourteen trials, only three studies were of high quality according to the Jadad-scale (with three score). There was one meta-analysis trial and the others, about ten trials, were of low quality. There was no trial which mentioned sample-size calculation, allocation concealment, intention-to-treat analysis. Most of the trials didn’t describe the blind-procedure. There were five trials which detailed the side-effects according to the toxicity grade by WHO standard. The side-effects halting treatment were haematologic and biochemical toxicity, debilitating nausea and vomiting. There were two patients died of chemotherapy toxicity.

CONCLUSION: Based on the review, intravenous chemotherapy after gastrectomy may have positive treatment effect on gastric cancer. However, the evidence is not strong because of the general low methodologic quality of the RCTs. Therefore, we can’t make the conclusion that intravenous chemotherapy after gastrectomy may have better treatment effect on gastric cancer than that of surgery alone. Rigorously designed, randomised, double-blind, placebo-controlled trials are required.

Hu J K, Chen Z X, Zhou Z G, Zhang B, Tian J, Chen J P, Wang L, Wang C H, Chen H Y, Li Y P. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol 2002;8(6):1023-1028

INTRODUCTION
Gastric cancer is one of the most common cancers worldwide. The outcome of patients with gastric carcinoma has recently been significantly improved with advances in experimental researches, early diagnosis and surgical techniques[1-44]. Although chemotherapy and radiation therapy have been tried as either an adjuvant or palliative treatment, their values are limited by toxicity or the lack of efficacy[45]. While surgery remains the mainstay of potentially curative treatment, survival rates for patients able to undergo complete resection are poor[46]. The five year survival rate for resected gastric cancer is about 30-60 % which has been disappointing. A number of studies have investigated whether intravenous chemotherapy after a resection improves the survival rate or not, but the results are different and disputed. Herrmans et al[47] reviewed the randomized controlled trials by meta-analysis, the results indicated that postoperative chemotherapy in general offered no additional survival benefit for patients with curatively resected gastric cancer. Janunger et al[48] performed a systematic overview of chemotherapy effects in gastric cancer by the Swedish Council...
of Technology Assessment in Health Care(SBU). A meta-analysis of 21 randomised adjuvant studies revealed a statistically significant survival benefit (OR=0.84, 95 % CI 0.74-0.96).

The aim of meta-analysis is to summarize the results of randomized trials performed to evaluate the effect of intravenous chemotherapy for gastric cancer[47]. The analysis is restricted to studies published since 1980. Surgical resection without any adjuvant therapy is considered standard treatment. Only intravenous chemotherapy trials with gastrectomy control arm were taken into consideration in this meta-analysis.

MATERIALS AND METHODS

Materials
Randomized or quasi-randomized trials comparing the efficacy of intravenous chemotherapy after gastrectomy with that of surgery alone in patients with confirmed gastric carcinomas who had received gastrectomy were included in this meta-analysis. Language was restricted to Chinese and English.

Selection criteria were: randomized or quasi-randomized trials with following-up results; Trials could be double-blind, single-blind or not blind; Chemotherapy groups were given intravenous chemotherapy after gastrectomy without neo-adjuvant chemotherapy, intraperitoneal hyperthermic perfusion, radiotherapy or chemoimmunotherapy; Controlled group included those receiving gastrectomy alone.

Exclusion criteria were: prior malignancy; neo-adjuvant chemotherapy, intraperitoneal hyperthermic perfusion, radiotherapy or chemoimmunotherapy; patients who didn’t receive gastrectomy; the controlled studies also included those without gastrectomy.

Methods
Search strategy Search was applied to the following electronic databases: the Cochrane Library, MEDLINE (1980-2001.4), EMBASE (1980-2001.4) and Chinese Bio-medicine Database (1990-2001/1). Literature reference proceedings were handsearched at the same time. The searching words were chemotherapy, stomach neoplasms and surgery.

Data collection and analysis Data were extracted independently by two reviewers. The methodological quality of trials was evaluated using the Jadad-scale plus allocation concealment. Intention-to-treat analyses were performed.

The following data were extracted: the number of survival and death by the end of the follow-up; the different agents and modalities; the number of patients treated; the follow-up time; the average sample size; the statistical consideration; cost-effectiveness analysis. Sensitivity analyses was performed by excluding the trials which Jadad-scale was only 1 score. The result was expressed with odds ratio(OR) for the categorical variable.

RESULTS
There were 1076 papers relevant to the searching words. Through the steps of screening the title, reading the abstract and the entire article, twenty-seven randomized trials were identified. Only fourteen randomized trials comparing the efficacy of intravenous chemotherapy after gastrectomy with that of surgery alone in patients with confirmed gastric carcinomas, including 4543 patients, met the inclusion criteria[47,49-56,1A-5A]. There were six trials which were excluded for repetitive studies[57-60,6A,7A], five for having been included in the result of the Hermans’ meta-analysis[61-65], two for no available data[66,67]. Of fourteen included trials, four trials were conducted in China (see appendix[2A-5A]), three in England[50,51,1A], two in Italy[49,54], two in Spain[51,56], one in Korea[52], Germany[53] and Netherland[47] respectively. The average sample size was 324 patients (from 25 to 1967 patients). The follow-up time was from forty-eight months to one hundred and twenty months. The chemotherapy regimens used were FAM,MFC,MNV,FMC,FEM and 5-FU+BCNU(Table 1). All the baselines of the trials were parallel. None of them performed the cost-effectiveness analysis.

Table 1 Data from 14 trials on intravenous chemotherapy versus surgery alone after resection for gastric cancer

| Author         | Published time | Chemotherapy regimen | Chemotherapy group (number of death/total) | Surgery group (number of death/total) | Follow-up (months) |
|----------------|----------------|----------------------|-------------------------------------------|---------------------------------------|-------------------|
| Lise           | 1995           | FAM                  | 88/163                                    | 99/163                                | 78                |
| Hallissey      | 1994           | FAM                  | 103/138                                   | 110/145                               | 60                |
| Estape         | 1991           | MMC                  | 16/33                                     | 31/37                                 | 120               |
| Kim            | 1992           | FM                   | 54/77                                     | 71/94                                 | 60                |
| Li LJ          | 1994           | FM+BCNU              | 167/208                                   | 282/341                               | 60                |
| Wang BD        | 1994           | FM+Ara-C             | 49/78                                     | 36/42                                 | 36                |
| Li HX          | 1994           | FM                   | 182/208                                   | 192/213                               | 60                |
| Coombes        | 1998           | FEM                  | 36/42                                     | 36/42                                 | 60                |
| Schlag         | 1987           | 5F6+BCNU             | 21/42                                     | 28/53                                 | 72                |
| Neri           | 1996           | Epidoxorubicin       | 36/48                                     | 48/55                                 | 36                |
| Zhou GX        | 1998           | FM                   | 35/41                                     | 38/40                                 | 60                |
| Lawton         | 1981           | 5F6+BCNU             | 11/13                                     | 10/12                                 | 60                |
| Cirera         | 1999           | MMC+TeGastrine       | 33/76                                     | 44/72                                 | 37                |
| Hermans        | 1993           | Meta-analysis        | 720/1098                                  | 589/869                               | NA                |

Abbreviations: F/5-Fu, fluorouracil; A,doxorubicin; M/MMC, mitomycin; C/Ara-C, cytarabine; E, etoposide; V,vindinblastine; BCNU,1,3-bis-(2-chloroethyl)-1-nitrosourea; NA, no available.

The effectiveness of intravenous chemotherapy after gastrectomy was better than surgery alone (odds ratio 0.56, 95 % CI 0.40-0.79). The results of the trials showed inconsistency, as checked by the chi-square test (χ²=52.54, P<0.0001). There was a significant difference between the two groups by t-test (P=0.0008) (Figure 1). By excluding the low quality trials[2A-5A], the sensitivity analysis was performed and revealed the same difference between chemotherapy and surgery alone (odds ratio 0.81, 95 % CI 0.70-0.94, P=0.005) (Figure 2).

Of fourteen trials, only three studies[49,50,56] were of high quality according to the Jadad-scale (with three score). There was one meta-analysis trial[47] and the others, about ten trials were of low quality. There was no trial which mentioned sample-size calculation, allocation concealment, intention-to-treat analysis. Most of the trials didn’t describe the blind procedure. Therefore, the methodologic quality of the RCTs is not strong enough to testify the conclusion.

There were five trials[49,53-56] which detailed the side-effects of medicine according to World Health Organization grade. The side-effects halting treatment were haematologic and biochemical toxicity, debilitating nausea and vomiting. There were two patients died of chemotherapeutic toxicity (one died of cardiac toxicity and the other of massive alimentary tract.
hemorrhage because of thrombopenia). Severe toxicity (grade 3 or 4 according to the WHO scale) occurred in 5.33%, with alopecia in 39 patients, leucopenia (WBC values less than 2000/µL) in 18, nausea in 21, thrombopenia (platelet count less than 50 000/µL) in 13, anemia in 9, vomiting in 5, diarrhea in 5, gastritis in 5, stomatitis in 4, cardiac toxicity in 4, septicemia in 2 and neural toxicity in 1.

**DISCUSSION**

It is well recognized that most patients who undergo curative resection of gastric carcinoma remain at high risk of local and systematic relapse. Thus, a worldwide effort has been done to develop effective adjuvant therapy to reduce this risk[46]. The aim of meta-analysis is to summarize the results of randomized trials performed to evaluate the effect of intravenous chemotherapy for gastric cancer. Surgical resection without any adjuvant therapy is considered standard treatment. Only intravenous chemotherapy trials with gastrectomy control arm were taken into consideration in this meta-analysis. There are two meta-analyses to assess the effect of intravenous chemotherapy for gastric cancer with gastrectomy. Hermans et al[47] researched the randomized controlled trials by meta-analysis; the results indicated that postoperative chemotherapy in general offered no additional survival benefit for patients with curatively resected gastric cancer. Janunger et al[48] performed a systematic overview of chemotherapy effects in gastric cancer by the Swedish Council of Technology.
Assessment in Health Care (SBU). A meta-analysis of 21 randomised adjuvant studies revealed a statistically significant survival benefit (OR=0.84, 95%CI 0.74-0.96). But we couldn’t get the original article of Janunger, therefore we didn’t include the trials in this meta-analysis.

Measuring an effect on survival by calculating the odds ratios was proved to be effective in an analysis[47]. Only four trials which were performed by Cerira[56], Estape[55], Li et al[24] and Wang et al[44] respectively, demonstrated a positive effect of intravenous chemotherapy versus the controlled group by calculating the odds ratios.

Of included fourteen trials, only three studies were of high quality according to the Jadad-scale. There was one meta-analysis trial and the others, about ten trials were of low quality. There was no trial which mentioned sample-size calculation, allocation concealment, intention-to- treat analysis. Therefore, the methodologic quality of the RCTs is not strong enough to testify the conclusion. Based on the review, intravenous chemotherapy after gastrectomy may have positive treatment effect on gastric cancer. However, the evidence is not strong because of the general low methodologic quality of the RCTs. Rigorously designed, randomised, double-blind, placebo-controlled trials are required.

The toxicity of medicine is an important factor to influence the outcome of the chemotherapy. But unfortunately, there were only five trials which detailed the side effects of medicine according to World Health Organization grade in this meta-analysis. Hence, in the future research, we should put in mind to observe the side effects carefully and describe them by the WHO grade standard.

Recently, such therapies as intraperitoneal hyperthermic perfusion[69-72], neo-adjuvant chemotherapy[75-78], radiotherapy[85-89] and chemoinmunotherapy[92] are demonstrated with a positive effect to reduce the relapse risk. Tao et al[90] revealed that preoperative regional artery chemotherapy had the effect to induce growth inhibition and apoptosis of gastric carcinoma cells. Cao et al[91] found that human primary gastric cancer cell in vitro were methionine-dependent; methionine-free environment might strengthen the killing effect of chemotherapy on human primary gastric cancer cells. But, the scientific conclusion should be supported by the high quality randomized, double-blind, placebo-controlled trials.

Appendix A. RCT reports retrieved in Chinese of chemotherapy for resected gastric cancer

1A Zhai Y, Ding DS. A controlled, randomised trial of adjuvant chemotherapy using FEM combination protocol in resectable gastric cancer. Guowai Yiya Kbangshengu Zazi 1998; 19: 150-151

2A Li LJ, Wang LY, Cai L, Zhao GF, Shi YQ, Wang ZY, Lin YJ. Combined treatment of surgery with chemotherapy of stomach cancer: an analysis 5-year following up of 649 patients. Shiyong Zhongliuxue Zazhi 1994; 8: 57-58,79

3A Li BX, Wang YB, Zhuang YZ. Clinical trial of perioperative chemotherapy using FM combination protocol in patient with gastric cancer. Zhongguo Zhongliuxue Linchuang 1994; 21: 604-606

4A Wang BD, Zhang GY, Leng GZ. The effect of chemotherapy in resectable gastric cancer. Dingzhang Zhongliuxue Zazhi 1994; 11:137-138

5A Zhou GX, Peng YM. Clinical study on the effect of chemical therapy to stomach cancer after operation. Zhongliu Fangshi Zazi 1998; 25: 294-295

6A Wang ZY, Jia SW, Li LJ, Cai YH, Bai YX, Li L, Yan ZJ, Dai HX. Combined treatment of surgery with chemotherapy of stomach cancer: an analysis 5-year following up of 170 patients. Hherbing Yike Dauxie Xuebao 1990; 24: 30-33

7A Chen W, Li RL, Sui GJ. Adjuvant chemotherapy can improve the late result of radical operation in patients with gastric cancer. Zhongliu Fangshi Yanzhu 1994; 21: 163-165

REFERENCES

1 Wang X, Lan M, Shi YQ, Lu J, Zhong YX, Wu HP, Zai HH, Ding J, Wu KC, Pan BR, Jin JP, Fan DM. Differential display of vincristine-resistance-related genes in gastric cancer SGC7901 cell. World J Gastroenterol 2002; 6: 224-229

2 Zhang XY. Some recent works on diagnosis and treatment of gastric cancer. World J Gastroenterol 1999; 5: 1-3

3 Zou SC, Qiu HS, Zhang CW, Tao HQ. A clinical and long-term follow-up study of peri-operative sequential triple therapy for gastric cancer. World J Gastroenterol 2000; 6: 284-286

4 Li Y, Yang L, Cui JT, Li WM, Guo RF, Lu YY. Construction of cDNA representation difference analysis based on two cDNA libraries and identification of gastric inducible expression genes in human gastric cancer cells. World J Gastroenterol 2002; 8: 208-212

5 Li Y, Lu YY. Applying a highly specific and reproducible cDNA RNA method to clone gastric up-regulated genes in human gastric cancer cells. World J Gastroenterol 2002; 8: 213-216

6 Liu JR, Li BX, Chen BQ, Han XH, Xue YB, Wang YM, Zheng YM, Liu RH. Effect of cis-9, trans-11-conjugated linoleic acid on cell cycle of gastric adenocarcinoma cell line (SGC-7901). World J Gastroenterol 2002; 8: 224-229

7 Tovey FI, Hobsley M. Post-gastrectomy patients need to be followed up for 20-30 years. World J Gastroenterol 2000; 6: 45-48

8 Hou P, Tu ZX, Xu GM, Gong YF, Ji XH, Li ZS. Helicobacter pylori vacA genotypes and cagA status and their relationship to associated diseases. World J Gastroenterol 2000; 6: 605-607

9 Deng DJ. Progress of gastric cancer etiology: N-nitrosamines in the 1990s. World J Gastroenterol 2000; 6: 613-616

10 Yin F, Shi YQ, Zhao WP, Xiaob, Miao YF, Fan DM. Suppression of P-gp induced multiple drug resistance in a drug resistant gastric cancer cell line by overexpression of Fas. World J Gastroenterol 2000; 6: 664-670

11 Cai L, Yu SZ, Ye WM, Yi YN. Fish sauce and gastric cancer: an ecological study in Fujian Province, China. World J Gastroenterol 2000; 6: 671-675

12 Li QF, Ou-Yang GL, Li CY, Hong SG. Effects of tachyplesin on the morphology and ultraducture of human gastric carcinoma cell line BGC-823. World J Gastroenterol 2000; 6: 676-680

13 Zhu JS, Su Q, Zhou JG, Hu PL, XuJH. Study of primary leiomyosarcoma induced by MNNG in BALB/C nude mice. World J Gastroenterol 2000; 6: 128-130

14 Cao WX, Cheng QM, Fei XF, Li SF, Yin HR, Lin YZ. A study of preoperative methionine-depleting parental nutrition plus chemotherapy in gastric cancer patients. World J Gastroenterol 2000; 6: 255-258

15 Tian XJ, Wu J, Meng L, Dong ZW, Shou CC. Expression of VEGF121 in gastric carcinoma MGC803 cell line. World J Gastroenterol 2000; 6: 281-283

16 Cai L, Yu SZ, Zhang ZF. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujian Province. Gastroenterol 2000; 6: 374-376

17 Zhang FX, Zhang X, Fan DM, Deng ZY, Yan Y, Wu HP, Fan J. Anti-sense telomerase RNA induced human gastric cancer cell apoptosis. World J Gastroenterol 2000; 6: 430-432

18 GuQL, Li NL, Zhu ZG, Yin HR, Lin YZ. A study on arsenic trioxide inducing in vitro apoptosis of gastric cancer cell lines. World J Gastroenterol 2000; 6: 435-437

19 WangZN, Xu HM. Relationship between collagen IV expression and biological behavior of gastric cancer. World J Gastroenterol 2000; 6: 438-439

20 HanFC, Yan XJ, Su CZ. Expression of the CagA gene of H. pylori and application of its product. World J Gastroenterol 2000;6:122-124

21 ChenGY, Wang DR. The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol 2000; 6: 125-127

22 TuoBG, Yan YH, GeZL, Ou GW, Zhao K. Ascorbic acid secretion in the human stomach and the effect of gastrin. World J Gastroenterol 2000; 6: 704-708

23 HuangXQ. Helicobacter pylori infection and gastrointestinal hormones: a review. World J Gastroenterol 2000; 6: 783-788

24 Gao HJ, Yu LZ, Bai JF, Peng YS, Sun G, Zhao HL, Miu K, LUXZ, Zhang XY, Zhao ZQ. Multiple genetic alterations and behavior...
of cellular biology in gastric cancer and other gastric mucosal lesions: H. pylori infection, histological types and staging. World J Gastroenterol 2000; 6: 848-854

25 Chen JP, Lin C, Xu CP, Zhang YX, Wu M. The therapeutic effects of recombinant adenosine RA538 on human gastric carcinoma cells in vitro and in vivo. World J Gastroenterol 2000; 6: 855-860

26 Zhou HP, Wang X, Zhang NZ. Early apoptosis in intestinal and diffuse gastric carcinomas. World J Gastroenterol 2000; 6: 898-903

27 Chen XO, Zhang YQ, Song YG, Zhou DY. Induction of apoptosis of lymphocytes in rat mucosal immune system. World J Gastroenterol 1998; 4: 19-23

28 Xiao B, Shi YQ, Zhao YQ, You H, Wang ZY, Liu XL, Yin F, Qiao TD, Fan D M. Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistant gastric cancer cells to chemotherapy drugs. World J Gastroenterol 1998; 4: 421-425

29 Wang XW, Xie H. Presence of Fas and Bcl-2 proteins in BEL-7404 human hepatoma cells. World J Gastroenterol 1998; 4: 540-543

30 Lu YF, Zhao G, Guo CY, Jia SR, Hou YD. Vagus effect on pylorus-preserving gastrectomy. World J Gastroenterol 1999; 5: 177-178

31 Liu HF, Liu WW, Fang DC, Men RP. Expression and significance of proapoptotic gene Bax in gastric carcinoma. World J Gastroenterol 1999; 5: 15-17

32 Li HL, Chen DD, Li XH, Zhang HW, Lu YQ, Ye CL, Ren XD. Changes of NF-kB, p53, Bcl-2 and casapse in apoptosis induced by JTE-522 in human gastric adenocarcinoma cell line AGS cells: role of reactive oxygen species. World J Gastroenterol 2002; 8: 431-435

33 He XS, Su Q, Chen ZC, He XT, Long ZF, Ling H, Zhang LR. Expression, deletion and mutation of p16 gene in human gastric cancer. World J Gastroenterol 2001; 7: 515-521

34 Han Y, Han ZY, Zhou XM, Shi R, Zheng Y, Shi YQ, Miao JY, Pan BR, Fan DM. Expression and function of classical protein kinase C isoforms in gastric cancer cell line and its drug-resistant sublines. World J Gastroenterol 2002; 8: 441-445

35 Ji F, Peng QB, Zhan JH, Li YM. Study of differential polymerase chain reaction of C-erbB-2 oncogene amplification in gastric cancer. World J Gastroenterol 1999; 5: 152-155

36 Xia L, Yuan YZ, Xu CD, Zhang YP, Qiao MM, Xu JX. Effects of epidermal growth factor on the growth of human gastric cancer cell and the implanted tumor nude mice. World J Gastroenterol 2002; 8: 453-458

37 Zhang Z, Yuan Y, Gao H, Dong M, Wang L, Gong YH. Apoptosis, proliferation and p53 gene expression of H. pylori associated gastric epithelial lesions. World J Gastroenterol 2001; 7: 779-782

38 Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, Wu LF, Zhu AL, Wang XQ, Wu M. Profiling of differentially expressed genes in human gastric carcinoma by cDNA expression array. World J Gastroenterol 2002; 8: 580-585

39 Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: A meta-analysis. World J Gastroenterol 2003; 7: 893-894

40 Miehlike S, Kirsch C, Dragosics B, Gschwantler M, Oberhuber G, Antos D, Dite P, Lutter J, Labenz J, Leodolter A, Malfertheiner P, Neubauer A, Ehninger G, Stolte M, Bayedrer R. Helicobacter pylori and gastric cancer: current status of the Austrian Cancer German German cancer prevention trial (PRISMA Study). World J Gastroenterol 2001; 7: 243-247

41 Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerous. World J Gastroenterol 2002; 8: 586-590

42 Song ZJ, Gong P, Wu YF. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-595

43 Ren J, Dong L, Xu CB, Pan BR. The role of KDR in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8: 596-601

44 Ren J, Dong L, Pan BR. Expression of chondroinosine kinase gene in the interactions between human gastric carcinoma cell and vascular endothelial cell. World J Gastroenterol 2002; 8: 602-607

45 Cunningham D, Hole D, Taggart DJ, Soukop M, Carter DC, Mcardle CS. Evaluation of the prognostic factors in gastric cancer: the effect of chemotherapy on survival. Br J Surg 1987;74:715-720

46 Averbach AM, Jacquet P. Strategies to decrease the incidence of intra-abdominal recurrence in resectable gastric cancer. Br J Surg 1996; 83: 726-733

47 Hermans J, Bonenkamp JJ, Boon MC, Bunt AMG, Ohyama S, Sasaki M, Van de Velde CJH. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 11: 1441-1447

48 Janunger KG, Hafstrom L, Nygren P, Gillemius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 2001; 40: 309-326

49 Lise M, Nitti D, Marchet A, Sahmoud T, Buyse M, Duez N, Fiorentino M, Santos JGD, Labianca R, Rougier P, Gignoux M. Final results of apahse III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimens in resectable gastric cancer. J Clin Oncol 1995; 13: 2757-2763

50 Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British stomach cancer group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312

51 Estape J, Grau J, Llobetendas F, Curto J, Daniels M, Vinolas N, Pera C. Mitomycin C as an adjuvant treatment to resected gastric cancer: a 10-year follow-up. Ann Surg 1999; 213: 219-221

52 Kim JP, Kwon OH, Oh ST, Yang HK. Results of surgery on 6589 gastric cancer patients and immunosocmumotherapy as the best treatment of advanced gastric cancer. Ann Surg 1999;212:269-279

53 Fan DM, Jia SR, Hou YD. Adjuvant chemotherapy in gastric cancer. World J Surg 1987; 11: 473-477

54 Neri B, Leonardis VD, Romano S, Andreoli F, Pernice LM, Bruno L, Borrelli D, Valeri A, Fabbrioni S, Intini C, Cini G. Adjuvant chemotherapy after gastric cancer in node-positive cancer patients: a multicentre randomised study. Br J Cancer 1996; 73: 549-552

55 Lawton JT, Gilles GR, Hall R, Bird GG, Matheson T. Chemotherapy following palliative resection of gastric cancer. Br J Surg 1998; 85: 739-744

56 Cirera L, Balli A, Alentorn EB, Tusquets I, Cardona T, Arcusa A, Jolis L, Saigl E, Guasch I, Badia A, Boleda M. Randomized clinical trial of adjuvant mitomycin plus Tegafur in patients with resected stage III gastric cancer. J Clin Oncol 1999; 17: 3810-3815

57 Allum WH, Hallissey MT, Ward LC, Hocke MSA controlled, prospective randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. Br J Cancer 1998; 60: 739-744

58 Allum WH, Hallissey MT, Kelly KA. Adjuvant chemotherapy in operable gastric cancer: 5 year follow-up of first British stomach cancer group trial. Lancet 1989; 1: 571-574

59 Yu CCW, Levison DA, Dunn JA, Ward LC, Demonacou M, Allum WH, Hallissey MT. Pathological prognostic factors in the second British stomach cancer group trial of adjuvant therapy in resectable gastric cancer. Br J Cancer 1995; 71: 1106-1110

60 Pignon JP, Ducrœux M, Rougier P. Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal. J Clin Oncol 1994; 12: 877-878

61 Enstrom PF, Lavin PT, Douglas HO, Brunner KW. Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Cancer 1985; 55: 1868-1873

62 Higgins GA, Amaddeo JL, Smith DE, Humphrey EW, Keehn RJ. Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. Cancer 1983; 52: 1105-1112

63 Bonfanti G, Tumori N. Adjuvant treatments following curative resection for gastric cancer. Br J Surg 1988; 75: 1100-1104

64 Douglas HO, Stabein DM. Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1962; 49: 1116-1122

65 Coombes RC, Schien PS, Chivers CED, Wils J, Beretta G, Bliss AM, Rutten A, Amadori D, Cortes-Funes H, Villar-Grimaldi A, Meffre S, Rauscher HF, Boven E, Vassilopoulos P, Veland V, Ferreira EP, Wiig J, Gisselbrecht C, Rougier P, Woods EM. A randomized trial comparing adjuvant fluorouracil, doxorubicin and mitomycin with no treatment in operable gastric cancer. J Clin Oncol 1990; 8: 1362-1369

66 Fielding JWL, Fagg SL, Jones BG, Ellis D, Hockey MS, Minawa
A. Brookes VS, Craven JL, Mason MC, Timothy A, Waterhouse JAH, Wrigley PFM. An interim report of a prospective, randomized, controlled study of adjuvant chemotherapy in operable gastric cancer: British stomach cancer group. World J Surg 1983;7:390-399

Krook JE, O’Connell MJ, Wierd HS, Beart RW, Leigh JE, Kugler JW, Foley JP, Peefle DM, Twito DI. A prospective, randomized evaluation of intensive-course 5-Fluorouracil plus Doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. Cancer 1991; 67: 2454-2458

Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years. Cancer 1999; 86: 1657-1668

Fujimoto S, Takahashi M, Muto M, Kobayashi K, Toyosawa T. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529-534

Yu W, Whang I, Suh I, Averbach A, Chang D, Sugarbaker PH. Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer. Ann Surg 1998; 228: 347-354

Rosen HR, Jatzko G, Repse S, Potoc S, Neudorfer H, Sandbicler P, Zacherl J, Rabi H, Holzberger P, Lisborg P, Czeljka M. Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian working group for surgical oncology. J Clin Oncol 1998; 16: 2733-2738

Sautner T, Hofbauer F, Depisch D, Schiessel R, Jakesz R. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12: 970-974

Yonemura Y, Fujimura T, Fushida S, Takegawa S, Kamata T, Katayama K, Kosaka T, Yamaguchi A, Miwa K, Miyazaki I. Hyperthermo-chemotherapy combined with cytoreductive surgery for the treatment of gastric cancer with peritoneal dissemination. World J Surg 1991; 15: 530-536

Hagiwara A, Takahashi T, Ueda T, Lee R, Takeda M, Itoh T. Intraperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. Surg 1988; 104: 874-871

Leichman L, Silberman H, Leichman CG, Spears CP, Ray M, Muggia FM, Kiyabu M, Radin R, Laine L, Stain S, Fuerst M, Brosken S, Donovan A. Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a university of Southern California pilot program. J Clin Oncol 1992; 10: 1933-1942

Kiyabu M, Leichman L, Chandrasoma P. Effects of preoperative chemotherapy on gastric adenocarcinomas: a morphologic study of 25 cases. Cancer 1992; 70: 2239-2245

Ajani JA, Ota DM, Jesup JM, Aimes FC, Mcbride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma: an evaluation of preoperative and postoperative chemotherapy. Cancer 1991; 68: 1501-1506

Yonemura Y, Sawat S, Kinoshita K, Matsu M, Fushida S, Tanaka S, Ohayama S, Takashima T, Kimura H, Kamata T, Fujimura T, Sugiyama K, Shima K, Miyazaki I. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg 1993; 17: 256-262

Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Rajmain I, Hargraves K, Curley S, Ota DM. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999; 17: 2401-2411

Fink U, Schuhmacher C, Stein HJ, Busch R, Feussner H, Dittler HJ, Helmbberger A, Bottenk K, Siewert JR. Preoperative chemotherapy for stage III-IV gastric carcinoma: feasibility, response and outcome after complete resection. Br J Surg 1995; 82:1249-1252

Wilke H, Preussner P, Fink U, Gunzer U, Meyer HJ, Meyer J, Siewert JR, Adereth W, Lenaz L, Kripp H, Schmoll HJ. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin, and cisplatin. J Clin Oncol 1989; 7: 1318-1326

Melcher AM, Mort D, Maughan TS. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer. Br J Cancer 1996; 74: 1651-1654

Sugamura K, Makino M, Shirai H, Kimura O, Maeda M, Itoh H, Kaibara N. Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer 1997; 79: 12-17

Becker K, Fumagalli U, Mueller JD, Fink U, Siewert JR, Hofler H. Neoadjuvant chemotherapy for patients with locally advanced gastric cancer. Cancer 1999; 85: 1489-1499

Lokich JJ, Shea M, Chaffey J. Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction. Cancer 1987; 60: 275-279

Gill PG, Jamieson GS, Denham J, Dervitt PG, Ahmad A, Yeoh E, Jones AM. Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy. Br J Surg 1990; 77: 1020-1023

Coia LR, Paul AR, Engstrom PF. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer 1988; 61: 643-649

Haas CD, Mansfield CM, Leichman LP, Considine B, Bukowski RM. Combined nonsimultaneous radiation therapy and chemotherapy with S-FU, Doxorubicin, and Mitomycin for residual localized gastric adenocarcinoma: a southwest oncology group pilot study. Cancer Treat Rep 1983; 67: 421-424

Weissberg JB. Role of radiation therapy in gastrointestinal cancer. Arch Surg 1983; 118: 96-104

Tao HQ, Zou SC. Effect of preoperative regional artery chemotherapy on proliferation and apoptosis of gastric carcinoma cells. World J Gastroenterol 2002; 8: 451-454

Cao WX, Ou JM, Fei XF, Zhu ZG, Yin HR, Yan M, Lin YZ. Methionine-dependence and combination chemotherapy on human gastric cancer cells in vitro. World J Gastroenterol 2002; 8: 230-232

Edited by Lu HM